Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal…

Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead…

In a remarkable declaration shaking the currents of contemporary science, two distinguished researchers at the Salk Institute have been elected…

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the…

Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has…

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy…

Novartis has penned a $2 billion deal for a biotech whose next-gen anti-immunoglobulin E (IgE) program could offer a worthy successor…